NCT03247686View on ClinicalTrials.gov

A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

July 15, 2018

Study Completion Date

August 1, 2019

Conditions
Sjogren's Syndrome
Interventions
DRUG

RSLV-132

RNase Fc fusion protein

DRUG

Placebo

Placebo

Trial Locations (2)

B16 6TT

University Hospitals Birmingham, Birmingham

NE3 3HD

Newcastle upon Tyne Hospitals, Newcastle upon Tyne

Sponsors
All Listed Sponsors
collaborator

University Hospital Birmingham

OTHER

collaborator

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

lead

Resolve Therapeutics

INDUSTRY